ArticleAIDS (London, England)2026

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

Christoph Wyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.